Loading stock data…
PGNY
$25.83-0.09 (-0.35%)
After Hours$26.21+0.38 (+1.47%)· Last close Jun 9
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Progyny, Inc. in the Healthcare sector is trading at $25.83 with a market capitalization of $2.0B. Wall Street consensus targets $29.73 (11 analysts), implying a +15.1% move over the next 12 months. The stock is currently 10% below its 52-week high of $28.75, remaining 17.6% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +15.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$25.83
Potential Upside
54.7%
Whystock Fair Value$39.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$29.73+15.1%
Range$26.00 – $31.00
Fundamentals
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cyc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.96B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
32.45
Beta
Defensive asset. Lower volatility than the S&P 500.
0.91
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.41%
Volume
Today's trading volume
1.53M
Recent News
Progyny (PGNY) Authorizes $200M Share Repurchase Program
Progyny, Inc. (NASDAQ:PGNY) is one of the 15 Most Promising Stocks to Buy Right Now. On May 26, 2026, Progyny, Inc. (NASDAQ:PGNY) announced that its Board of Directors approved a share repurchase program to buy back up to $200 million of the company’s common stock. The program will be funded through available cash balances. On […]
Conservative Guidance Weighed on Progyny (PGNY) Amid Strong Demand and Solid Execution
Voya Investment Management, an investment management company, released its first-quarter 2026 investor letter for its “Voya MI Dynamic Small Cap Fund.” It is an actively managed US Small Cap core equity strategy. A copy of the letter can be downloaded here. The first quarter of 2026 was challenging for the equity markets as easing inflation […]
3 Cash-Heavy Stocks That Concern Us
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
A Progyny (PGNY) Insider Sold 5,500 Shares for $137,000
Progyny delivers fertility benefits to major employers; a key insider recently trimmed their stake, according to SEC filings.
Progyny (PGNY) Is Up 7.0% After Analyst Upgrade Backed By Six Earnings Beats And 2026 Outlook
Earlier this week, fertility benefits provider Progyny received an analyst upgrade after reporting six consecutive quarters of revenue and adjusted EBITDA results above expectations and outlining plans for a return to double-digit revenue growth in the second half of 2026. This combination of consistent financial outperformance and a more upbeat growth outlook raises fresh questions about how Progyny is positioned within the managed health care benefits landscape. We’ll now examine how the...